FIT Test and Stool DNA Tests (Cologuard) as Alternatives to Colonoscopy — What Do the Numbers Show?

Colonoscopy, as we cover in more depth in our knowledge-base entry on the procedure, is the only widely available screening test that doesn't just detect colorectal cancer but actually prevents it, by removing precancerous polyps in the same session. The problem is that despite this proven effectiveness, the share of people who actually complete screening in the general population remains lower than the guidelines alone would suggest. The reasons are well known: the need to prep the bowel with a purgative, intravenous sedation that requires someone to accompany you afterward, a day off work, and, for some people, plain fear of an invasive procedure.

In response to this barrier, two widely used non-invasive alternatives have developed: the fecal immunochemical test (FIT), which detects occult blood, and the stool DNA test, sold in the US under the brand name Cologuard, which combines occult-blood detection with analysis of altered DNA shed by cancerous and precancerous cells into the stool. Both tests are done at home without any bowel prep, without sedation, and without losing a workday — the sample is then mailed to a lab.

This article isn't an argument that non-invasive tests are "just as good" as colonoscopy — they aren't, and presenting that trade-off honestly is exactly the point of this piece. What we do is lay out the concrete numbers from the most important available comparative study, so readers can understand the real difference between "the diagnostically superior test" and "the test that actually gets done" — and why, in population-level screening, both of those variables matter.

The FIT test detects human hemoglobin in stool using monoclonal antibodies specific to that protein. Adenomatous polyps and early colorectal cancers tend to have a more fragile, richly vascularized surface than normal mucosa, so they bleed microscopically more often, though not always, as stool passes over them. FIT, unlike the older guaiac-based tests, is specific to human hemoglobin, so it doesn't react to hemoglobin from food (such as red meat) and requires no dietary restrictions before testing — a common drawback of the older generation of tests.

The stool DNA test goes a step further: besides detecting occult blood immunochemically, it also analyzes shed intestinal cells in the stool for characteristic molecular changes — mutations in tumor suppressor genes (e.g. KRAS) and altered methylation patterns (e.g. in the NDRG4 and BMP3 genes) that are common in adenoma and colorectal cancer cells but rare in normal mucosa. Because cancerous and precancerous cells shed into the bowel lumen regardless of whether a given lesion happens to be actively bleeding at that moment, a DNA test should, in theory, detect more lesions than FIT, which only assesses bleeding — and, as the key comparative study shows, that's in fact what happens in practice.

The strongest available evidence comparing the sensitivity and specificity of both non-invasive tests against colonoscopy is a large study published in the New England Journal of Medicine in 2014, funded by the DNA test's manufacturer but designed in a way that allows for a fair comparison — every participant underwent all three tests (FIT, the DNA test, and colonoscopy), which eliminates the problem of comparing different patient populations.

These numbers show a clear, predictable pattern: the DNA test detects more real cases of cancer and advanced precancerous lesions (higher sensitivity), but at the cost of more false positives in people who, in reality, don't have a significant lesion (lower specificity). FIT works the other way around — it raises fewer false alarms, but also misses a larger share of real cases than the DNA test. Neither non-invasive test comes close to colonoscopy, though, which in this same study served as the reference standard defining what counts as a "true" positive result.

It's worth paying attention to the row on precancerous lesions — that's where the difference is largest and clinically most meaningful. Colonoscopy prevents cancer mainly by detecting and removing adenomas before they turn malignant. A test with 23.8% sensitivity (FIT) for these specific lesions misses more than three out of every four advanced precancerous lesions present in a given person at that moment — even the DNA test, better in this respect, still misses the majority of them (42.4% sensitivity means more than half go undetected). This is the single most important number in the whole comparison, and the reason neither non-invasive test is considered equivalent to colonoscopy for cancer prevention, only for early detection.

This reasoning isn't an argument that FIT is "as good as" colonoscopy at the level of a single patient — for any given individual, colonoscopy remains the more sensitive test and, unlike non-invasive tests, able to remove a lesion in the same session. It does explain, though, why screening guidelines in many countries formally accept FIT as an equally valid screening option alongside colonoscopy, not merely as a "lesser substitute for people who refuse the better test" — provided the test is repeated annually and every positive result is followed, without exception, by a colonoscopy.

The flip side of this myth can be just as dangerous: a negative non-invasive test result, especially with FIT, doesn't fully rule out a precancerous lesion — at 23.8% sensitivity for advanced precancerous lesions, most such lesions will go undetected in a single test. That's why FIT only makes sense as a test repeated every year, not as a one-time, final risk assessment — a single negative result is not a reason to stop regular screening in future years.

It's also worth noting that the cost and availability of both non-invasive tests vary considerably between countries and healthcare systems — in Poland, the availability of FIT testing through screening programs is currently far broader than the stool DNA test, which in many European countries remains harder to access or requires a commercial purchase. That practical limitation, independent of diagnostic performance itself, is worth factoring into the choice of method.

The most honest summary of this data isn't picking the "better" test — it's recognizing that the best screening test is the one that actually gets done, and repeated. Colonoscopy remains the gold standard and the only method that combines detection with prevention by removing precancerous lesions, so for people without significant barriers it's still the recommended first choice. Non-invasive tests, though, aren't a "lesser option for people who don't care" — they're a medically recognized, evidence-backed alternative for people for whom a real barrier (invasiveness, time, fear) would otherwise mean no screening at all. The key is not mistaking a non-invasive test's lower sensitivity for false reassurance — regularity of repetition and an unconditional follow-up colonoscopy after every positive result are the conditions without which neither test makes sense.